Subthreshold activation of the melanocortin system causes generalized sensitization to anorectic agents in mice.
J Clin Invest · 2024
Last updated 2026-05-28In mice, blocking or removing a specific receptor (MC3R) or using very low doses of another related compound (MC4R agonist) made them more sensitive to GLP-1 drugs, as well as other appetite-suppressing treatments like PYY, CCK, and leptin. This increased sensitivity led to greater reductions in food intake and weight loss when these treatments were given. The effect was observed without the side effects typically caused by GLP-1 drugs, suggesting potential benefits for obesity treatments.
AI summary of the abstract below.
| Journal | J Clin Invest, 2024 |
|---|---|
| Citations | 9 |
| Relative citation ratio | 1.88 |
| NIH percentile | 72 |
| Molecules | — |
| Conditions studied | Obesity |
Abstract
The melanocortin-3 receptor (MC3R) regulates GABA release from agouti-related protein (AgRP) nerve terminals and thus tonically suppresses multiple circuits involved in feeding behavior and energy homeostasis. Here, we examined the role of the MC3R and the melanocortin system in regulating the response to various anorexigenic agents. The genetic deletion or pharmacological inhibition of the MC3R, or subthreshold doses of an MC4R agonist, improved the dose responsiveness to glucagon-like peptide 1 (GLP1) agonists, as assayed by inhibition of food intake and weight loss. An enhanced anorectic response to the acute satiety factors peptide YY (PYY3-36) and cholecystokinin (CCK) and the long-term adipostatic factor leptin demonstrated that increased sensitivity to anorectic agents was a generalized result of MC3R antagonism. We observed enhanced neuronal activation in multiple hypothalamic nuclei using Fos IHC following low-dose liraglutide in MC3R-KO mice (Mc3r-/-), supporting the hypothesis that the MC3R is a negative regulator of circuits that control multiple aspects of feeding behavior. The enhanced anorectic response in Mc3r-/- mice after administration of GLP1 analogs was also independent of the incretin effects and malaise induced by GLP1 receptor (GLP1R) analogs, suggesting that MC3R antagonists or MC4R agonists may have value in enhancing the dose-response range of obesity therapeutics.
Verbatim abstract via PubMed 39007271 ↗